Compare Raytheon Technologies Corp (RTX) vs 10X Genomics Inc (TXG) Price & Performance

RTX trades at $197.55, down 1.61% today, but maintains a bullish technical outlook with strong support near $197 and resistance at $200. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.75. Revenue growth accelerated to $88.6 billion in 2025, with net income reaching $6.73 billion. Recent contract wins include a $515 million U.S. Navy radar award announced June 3, 2026.

Outlook remains positive with 65% analyst buy ratings and a $235.33 price target implying 19% upside. Key risks include execution challenges in scaling munitions production and dependence on defense budgets. Strong cash flow generation and expanding margins support continued dividend payments, with the next $0.73 dividend payable September 3, 2026.

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.